Zyn US shipment volume in Q1 2026

View on Kalshi Expiration: May 22, 2026 Updated: April 17, 2026 Companies KPIs Philip Morris KPI tracker

By Octagon Research. Generated by Octagon's research engine from live market data and the cited sources. Not individually reviewed unless a reviewer is named. How this report is made

Short Answer

Both the model and the market expect Zyn US shipment volume to be above 185 million in Q1 2026, with no compelling evidence of mispricing.

1. Market Behavior & Drivers

This prediction market is newly established and has not yet developed a trading history. The price has remained static at its opening level of 60.0%, indicating a flat or sideways trend. With only a single data point recorded, there have been no price movements, spikes, or drops to analyze. Consequently, it is not possible to correlate price action with any external news or developments. The market's stability is a result of inactivity rather than a consensus reached through active trading.

The total trading volume of 200 contracts was likely executed at the market's inception, establishing the initial 60.0% price. This volume shows some initial interest, but without subsequent trading, it is difficult to assess market conviction or identify any volume patterns. Because the price has not moved from its starting point, no support or resistance levels have been formed. The 60.0% mark is the only significant price point, representing the market's opening assessment.

Overall, the chart reflects a nascent market. The initial sentiment places the probability of the event occurring at 60.0%. However, this sentiment is untested and has not been challenged or confirmed by further trading activity. The lack of price discovery means the current price reflects only the opinion of the earliest participants.

PMI significantly expanded Zyn U.S. production capacity, including new plant.
FDA authorized 20 ZYN nicotine pouch products for U.S. marketing.
PMI projects 15-20% Zyn U.S. shipment growth year-over-year for 2026.
PMI prioritizes Zyn supply for robust U.S. market demand and growth.
Oral nicotine pouch use significantly increased, especially among younger demographics.
Velo notably increased its U.S. nicotine pouch market share.

2. Price Chart

Historical Price (Probability)

Outcome probability

Date

3. Significant Price Movements

Notable price changes detected in the chart, along with research into what caused each movement.

Outcome: above 195 million

📉 April 17, 2026: 17.0pp drop

Price decreased from 50.0% to 33.0%

What happened: No supporting research available for this anomaly.

📉 April 16, 2026: 10.0pp drop

Price decreased from 60.0% to 50.0%

What happened: No supporting research available for this anomaly.

📈 April 15, 2026: 16.0pp spike

Price increased from 44.0% to 60.0%

What happened: No supporting research available for this anomaly.

Outcome: above 205 million

📉 April 14, 2026: 19.0pp drop

Price decreased from 41.0% to 22.0%

What happened: No supporting research available for this anomaly.

Outcome: above 200 million

📉 April 13, 2026: 58.0pp drop

Price decreased from 87.0% to 29.0%

What happened: No supporting research available for this anomaly.

4. Market Data

Contract Snapshot

The market resolves to YES if Philip Morris International Inc. reports Zyn US shipment volume above 185,000,000 in Q1 2026, with the outcome verified by Fiscal.ai; otherwise, it resolves to NO. Trading for this market began on April 17, 2026, at 12:30 pm EDT. The market will close early if the event occurs, or by May 22, 2026, at 6:00 am EDT, with projected payouts 30 minutes after closing.

Market Discussion

Traders are generally optimistic about Zyn US shipment volume in Q1 2026, with a 56% chance predicted for volumes above 185 million. Many individual participants are betting "Yes" on even higher thresholds, specifically above 200 million and 205 million, citing strong "supply...demand." While there's bullish sentiment among posters, the probability for shipments above 195 million has significantly dropped by 30 points, suggesting some caution at the highest predicted volumes.

5. What is PMI's Zyn U.S. Production Capacity by Q1 2026?

Kentucky Facility Expansion Operational	Second half of 2025 ^[1]
Colorado Zyn Facility Official Opening	February 2026 ^[2]
Colorado Facility Production Capacity Target	300 million cans annually by end of 2026 ^[2]

Philip Morris International (PMI) is significantly expanding Zyn production with a new Colorado plant. The company has invested $600 million in a new Zyn production facility in Aurora, Colorado, which officially opened in February 2026 ^[2]. This facility is designed to achieve an initial annualized production capacity of 300 million cans by the end of 2026, with long-term plans to scale up to 700 million cans annually by 2028 ^[2].

Key operational expansions confirm increased capacity by early 2026. PMI is investing an additional $232 million in its existing Owensboro, Kentucky, facility, with the expansion projected to be fully operational by the second half of 2025 ^[1]. This particular milestone indicates a substantial increase in operational capacity that would be active at the start of Q1 2026. Furthermore, the Colorado plant had already commenced producing Zyn pouches in limited quantities during its construction phase, preceding its official opening in February 2026 ^[3].

A precise total Zyn capacity for Q1 2026 remains unspecified. While the research outlines the new Colorado plant's capacity targets for the end of 2026 and subsequent years, and confirms the operational timeline for the Kentucky expansion by H2 2025, a precise aggregated figure for the total annualized Zyn production capacity across all U.S. facilities specifically at the start of Q1 2026 is not provided in the available materials.

Sources (3)

6. How Have Zyn's Competitors Impacted Nicotine Pouch Market Share?

Velo U.S. Market Share	10% ^[1]
Zyn U.S. Market Share	55% ^[2]
Altria 'On!' Brand Performance	Steady growth ^[3]

Velo has notably increased its U.S. nicotine pouch market share. This primary competitor to Zyn saw its market share rise from 7.9% to 10% ^[2]. Concurrently, Zyn's market share decreased to 55%, and its overall growth rate experienced a notable slowdown ^[2]. These shifts indicate a strengthening competitive environment within the nicotine pouch sector.

Altria's 'On!' also demonstrates steady growth and market influence. This key brand has shown consistent expansion within the nicotine pouch segment and has been called a "game changer" ^[4]. The brand strengthens Altria's position in the broader oral tobacco market, where nicotine pouches now comprise 55.7% of the total market ^[3]. While specific quarter-over-quarter data through Q4 2025 is not detailed, the general trends underscore increasing competition and diversification among nicotine pouch brands.

Sources (4)

7. Has FDA Restricted Sales of ZYN Flavored Nicotine Pouches?

FDA Authorization Date	January 13, 2025 ^[1]
Authorized ZYN Products	20 nicotine pouch products ^[1]
Sales Restriction Status (End of 2025)	No definitive rulings or proposed rulemakings ^[1]

The FDA's CTP authorized 20 ZYN nicotine pouch products for marketing. On January 13, 2025, the U.S. Food and Drug Administration's Center for Tobacco Products (CTP) authorized the marketing of 20 ZYN nicotine pouch products following an extensive scientific review of their Premarket Tobacco Product Applications (PMTAs) ^[1]. This authorization includes popular flavors such as Citrus, Cool Mint, Peppermint, Spearmint, Wintergreen, Menthol, and Cinnamon, indicating these products met the FDA's rigorous standards for market entry ^[1].

No FDA rulemakings restrict ZYN's popular flavors by 2025. Contrary to the premise of sales restrictions, the FDA's actions by the end of 2025 have been to authorize the marketing of these flavored oral nicotine pouches ^[1]. The available research does not indicate any definitive rulings or proposed rulemakings issued by the FDA CTP by the end of 2025 that would restrict the sales of ZYN's most popular flavors ^[1]. These marketing orders permit the continued sale of these products unless the FDA were to withdraw them ^[1].

Sources (1)

1FDA Authorizes Marketing of 20 ZYN Nicotine Pouch Products after Extensive Scientific Review | FDAfda.gov

8. How is Oral Nicotine Pouch Use Growing Among Young Adults?

Nicotine Pouch Use Trend	Surge and sharp increase among youth and young adults ^[1]
Key Demographic	Youth and young adults, including 18-34 age group ^[2]
Q1-Q3 2025 Data Availability	Reports covering sales data and market trends available ^[3]

Oral nicotine pouch penetration has significantly increased, particularly among younger demographics. Web research indicates a substantial rise in oral nicotine pouch use, specifically within the 18-34 age group. Reports highlight a "surge" in nicotine pouch use among young people ^[1] and a "sharp increase" among teens ^[4]. Further studies examining awareness and use of oral nicotine pouches between 2022 and 2024 also confirm a growing prevalence in youth and young adult populations ^[2].

Specific growth rates and evidence of deceleration are not directly available from source titles. While precise quantitative data on growth rates or signs of market saturation for the first three quarters of 2025 could not be directly extracted from the available source titles, relevant reports are identified. These include a "Nicotine Pouch Sales Data Brief" updated to August 10, 2025, and a "Nicotine Pouch Market Report Q3 2025" ^[3]. Such documents are expected to contain detailed information on sales volumes, market trends, growth rates, and potential indicators of deceleration or saturation within the specified timeframe.

Sources (4)

9. Will Zyn U.S. Supply Be Capped for Global Growth?

2026 U.S. Shipment Growth	approximately 15-20% year-over-year ^[1]
Total Zyn Capacity Increase by mid-2026	approximately 25% ^[2]
Planned International Markets (Initial)	3-5 priority markets ^[1]

Philip Morris International's stated priority for Zyn supply allocation focuses on robust existing demand and continued growth in the U.S. market, concurrently allocating incremental capacity for strategic international expansion ^[1]. There is no guidance suggesting a potential cap on U.S. shipments; instead, the company is significantly expanding its total manufacturing capacity to support both domestic and global objectives ^[1]. PMI's strategy emphasizes maximizing Zyn's global potential while firmly anchoring its supply strategy on the established U.S. market, which it identifies as the largest and most profitable ^[3].

International expansion for Zyn will commence in 3-5 markets in 2026. PMI plans initial, controlled launches in these priority international markets, with entries projected to begin in 2026 ^[1]. A portion of the incremental manufacturing capacity will support these international allocations. The company is carefully planning these deployments to avoid significant disruption to the U.S. supply, underscoring its commitment to meeting existing U.S. demand ^[4].

Significant manufacturing expansion supports Zyn's future growth. PMI anticipates a substantial increase in total Zyn production capacity, estimated at approximately 25% by mid-2026 ^[2]. For 2026, Zyn U.S. shipment volumes are projected to grow by approximately 15-20% year-over-year, supported by continued demand and expanded production capabilities ^[1]. Management has clarified that while U.S. Zyn shipment volumes are expected to continue growing strongly, this growth will occur at a more measured pace than the explosive expansion seen in 2025, as production fully catches up with demand ^[1].

Sources (4)

HUMAN MACHINE